296 related articles for article (PubMed ID: 16464524)
1. The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development.
Dobo KL; Greene N; Cyr MO; Caron S; Ku WW
Regul Toxicol Pharmacol; 2006 Apr; 44(3):282-93. PubMed ID: 16464524
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of the sensitivity of the Ames assay to discern low-level mutagenic impurities.
Kenyon MO; Cheung JR; Dobo KL; Ku WW
Regul Toxicol Pharmacol; 2007 Jun; 48(1):75-86. PubMed ID: 17379368
[TBL] [Abstract][Full Text] [Related]
3. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity.
Müller L; Mauthe RJ; Riley CM; Andino MM; Antonis DD; Beels C; DeGeorge J; De Knaep AG; Ellison D; Fagerland JA; Frank R; Fritschel B; Galloway S; Harpur E; Humfrey CD; Jacks AS; Jagota N; Mackinnon J; Mohan G; Ness DK; O'Donovan MR; Smith MD; Vudathala G; Yotti L
Regul Toxicol Pharmacol; 2006 Apr; 44(3):198-211. PubMed ID: 16412543
[TBL] [Abstract][Full Text] [Related]
4. Overview of genotoxic impurities in pharmaceutical development.
Bercu JP; Dobo KL; Gocke E; McGovern TJ
Int J Toxicol; 2009; 28(6):468-78. PubMed ID: 19966139
[TBL] [Abstract][Full Text] [Related]
5. A perspective on testing of existing pharmaceutical excipients for genotoxic impurities.
Brusick DJ
Regul Toxicol Pharmacol; 2009 Nov; 55(2):200-4. PubMed ID: 19607870
[TBL] [Abstract][Full Text] [Related]
6. Control and analysis of alkyl and benzyl halides and other related reactive organohalides as potential genotoxic impurities in active pharmaceutical ingredients (APIs).
Elder DP; Lipczynski AM; Teasdale A
J Pharm Biomed Anal; 2008 Nov; 48(3):497-507. PubMed ID: 18657926
[TBL] [Abstract][Full Text] [Related]
7. Analytical control of genotoxic impurities in the pazopanib hydrochloride manufacturing process.
Liu DQ; Chen TK; McGuire MA; Kord AS
J Pharm Biomed Anal; 2009 Sep; 50(2):144-50. PubMed ID: 19427156
[TBL] [Abstract][Full Text] [Related]
8. Quantitative assessment of cumulative carcinogenic risk for multiple genotoxic impurities in a new drug substance.
Bercu JP; Hoffman WP; Lee C; Ness DK
Regul Toxicol Pharmacol; 2008 Aug; 51(3):270-7. PubMed ID: 18550240
[TBL] [Abstract][Full Text] [Related]
9. Determination of compound-specific acceptable daily intakes for 11 mutagenic carcinogens used in pharmaceutical synthesis.
Ellis P; Kenyon M; Dobo K
Regul Toxicol Pharmacol; 2013 Mar; 65(2):201-13. PubMed ID: 23228434
[TBL] [Abstract][Full Text] [Related]
10. Potentially mutagenic impurities: analysis of structural classes and carcinogenic potencies of chemical intermediates in pharmaceutical syntheses supports alternative methods to the default TTC for calculating safe levels of impurities.
Galloway SM; Vijayaraj Reddy M; McGettigan K; Gealy R; Bercu J
Regul Toxicol Pharmacol; 2013 Aug; 66(3):326-35. PubMed ID: 23688841
[TBL] [Abstract][Full Text] [Related]
11. Recent developments in the risk assessment of potentially genotoxic impurities in pharmaceutical drug substances.
Humfrey CD
Toxicol Sci; 2007 Nov; 100(1):24-8. PubMed ID: 17656486
[TBL] [Abstract][Full Text] [Related]
12. A quality evaluation strategy for multi-sourced active pharmaceutical ingredient (API) starting materials.
Gavin PF; Olsen BA; Wirth DD; Lorenz KT
J Pharm Biomed Anal; 2006 Jun; 41(4):1251-9. PubMed ID: 16621411
[TBL] [Abstract][Full Text] [Related]
13. Identification, control strategies, and analytical approaches for the determination of potential genotoxic impurities in pharmaceuticals: a comprehensive review.
Reddy AV; Jaafar J; Umar K; Majid ZA; Aris AB; Talib J; Madhavi G
J Sep Sci; 2015 Mar; 38(5):764-79. PubMed ID: 25556762
[TBL] [Abstract][Full Text] [Related]
14. Improved in silico prediction of carcinogenic potency (TD50) and the risk specific dose (RSD) adjusted Threshold of Toxicological Concern (TTC) for genotoxic chemicals and pharmaceutical impurities.
Contrera JF
Regul Toxicol Pharmacol; 2011 Feb; 59(1):133-41. PubMed ID: 20933038
[TBL] [Abstract][Full Text] [Related]
15. Toxicological overview of impurities in pharmaceutical products.
Jacobson-Kram D; McGovern T
Adv Drug Deliv Rev; 2007 Jan; 59(1):38-42. PubMed ID: 17188779
[TBL] [Abstract][Full Text] [Related]
16. In silico approaches to predicting cancer potency for risk assessment of genotoxic impurities in drug substances.
Bercu JP; Morton SM; Deahl JT; Gombar VK; Callis CM; van Lier RB
Regul Toxicol Pharmacol; 2010; 57(2-3):300-6. PubMed ID: 20363275
[TBL] [Abstract][Full Text] [Related]
17. Strategies for the identification, control and determination of genotoxic impurities in drug substances: a pharmaceutical industry perspective.
Raman NV; Prasad AV; Ratnakar Reddy K
J Pharm Biomed Anal; 2011 Jun; 55(4):662-7. PubMed ID: 21193280
[TBL] [Abstract][Full Text] [Related]
18. Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing.
Thybaud V; Aardema M; Clements J; Dearfield K; Galloway S; Hayashi M; Jacobson-Kram D; Kirkland D; MacGregor JT; Marzin D; Ohyama W; Schuler M; Suzuki H; Zeiger E;
Mutat Res; 2007 Feb; 627(1):41-58. PubMed ID: 17126066
[TBL] [Abstract][Full Text] [Related]
19. Characterization and validation of an in silico toxicology model to predict the mutagenic potential of drug impurities.
Valerio LG; Cross KP
Toxicol Appl Pharmacol; 2012 May; 260(3):209-21. PubMed ID: 22426359
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in trace analysis of pharmaceutical genotoxic impurities.
Liu DQ; Sun M; Kord AS
J Pharm Biomed Anal; 2010 Apr; 51(5):999-1014. PubMed ID: 20022442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
